Last Updated on September 19, 2025 by The Health Master
Clinical Trials
A draft published by the Union Health Ministry could change the drug approval game in the country, for it includes newly proposed guidelines that will create easier pathways to manufacturing and clinical trials for lifesaving drugs.
This could be beneficial for large pharmaceutical companies as well as small private research hospitals.
Why Update the System?
The current process is tedious and requires extensive documentation; questions and answers and subsequent approvals take so long that precious research time is lost.
Therefore, the Ministry of Health wants to establish a 50% reduced approval timeline for licensing to manufacture drugs as well as clinical trials.
- Present approval timeline: Up to 90 working days
- Proposed approval timeline: 45 working days
Such changes to the clinical trials process would render India a much more accessible and available country for large pharmaceutical company trials, as some approvals take less time than in other nations—and India is a diverse nation, bringing new potential to international firms while offering India new capital infusions.
Finding Easier Access
Perhaps the most intriguing aspect of this proposal states that stakeholders can now notify authorities (virtually) without seeking prior formal approval for products that are made strictly for testing/preclinical assessment purposes.
This is critical for basic science, as findings must be tested almost immediately.
However, some caveats exist. The draft simplifies the traditional pathway for the majority of new drugs sourced and manufactured, excluding:
- Sex hormones
- Cytotoxic drugs
- Beta-lactam drugs
- Biologics with live microorganisms
- Narcotics & psychotropic drugs
For these selected substances, the longer pathways of approval will remain in place for safety and compliance reasons.
When Will The Draft Be Approved/Disapproved?
As it stands, this is all subject to change. There is a 30-day window for any corporation, researcher, or layperson to comment on the draft proposal.
Such efforts show the government’s desire to work with industry professionals and voices to create a streamlined, cohesive process as India’s manufacturing abilities grow stronger and more necessary in international healthcare efforts.
Q: What do the proposed amendments aim to change?
A: Proposed amendments seek to reduce timelines dramatically for approvals for manufacturing and subsequent clinical trial permissions in India.
Q: Does this apply to all drugs?
A: No. Although the expedited process will be categorized for the majority of new drug approvals, sex hormones, cytotoxic drugs, narcotics, psychotropic drugs, and any potentially harmful substances still require permission from the Central Licensing Authority.
Q: Where can I comment about the proposal?
A: The Union Health Ministry has opened a 30-day comment period for relevant parties—pharmaceutical companies, researchers, and the layperson—to comment on the proposed drafts.
Disclaimer: This article contains information obtained from the source mentioned below. Our team made changes in the format to rewrite and present the news or article in a unique format.
Forms: All types of Clinical Trials
Schedules: All types of Clinical Trials
Latest Notifications: New Drugs and Clinical Trials
Other details about New Drugs, FDCs, Clinical trial
List of approved FDCs (Fixed Dose Combinations) Updated
FAQ-dt-18-02-2020-CDSCO-on-New-Drugs-and-Clinical-Trial
FAQ-dt-23-08-19-CDSCO-on-New-Drugs-and-Clinical-Trail
Transforming Clinical Research Sector in India
Clinical Trials of TB Vaccines: Recommendations from the Parliamentary Panel
NPPA fixed retail price of 42 formulations: August 2025
New Draft Standards for TB IVD Medical Devices: CDSCO
Drug alert: 143 drug samples declared as NSQ in July 2025
Key Notes on Revised Schedule M: API Part-6
USFDA inspection: At Sun Pharma with 8 observations: Halol
Action on Fake Doctor for selling Expired Drugs: Kerala
India to Track Antibiotic Use in Animals
7 new Medical Device Testing Laboratories (MDTLs)
